Skip to content
preclinicalImmune & Inflammation

Chonluten

Also known as: Thr-Glu-Asp-Gly, TEDG tetrapeptide, Respiratory bioregulator

Chonluten (Thr-Glu-Asp-Gly) is a synthetic tetrapeptide bioregulator targeting respiratory and bronchial tissue. Developed by Khavinson, it is proposed to modulate gene expression in lung epithelial cells. Preclinical studies report restoration of respiratory epithelium function and reduction of inflammatory markers in lung tissue of aged animal models.

2 cited references·2 researched benefits

Quick Answer

Chonluten (Thr-Glu-Asp-Gly) is a synthetic tetrapeptide bioregulator targeting respiratory tissue gene expression. Part of the Khavinson bioregulator family, preclinical research suggests it restores lung epithelial function and reduces pulmonary inflammation in aged animal models. It represents a peptide-based approach to respiratory tissue maintenance and may support bronchial health through epigenetic modulation.

Key Facts

Mechanism
Chonluten is proposed to interact with DNA regulatory regions in bronchial epithelial and alveolar cells, modulating genes involved in mucociliary clearance, surfactant production, and immune defense. The peptide may alter chromatin structure in lung-specific genetic loci, restoring youthful gene expression patterns in aging respiratory tissue.
Research Status
preclinical
Half-Life
~1–2 hours (estimated)
Molecular Formula
C₁₄H₂₃N₃O₉
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Respiratory support — may restore lung epithelial function in aging tissuepreliminary
  • Anti-inflammatory — reduces pulmonary inflammatory markers in preclinical modelspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use only10–100 mcgVariablePreclinical research compound. No approved therapeutic dosing.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • No significant adverse effects reported in preclinical studiesrare

Frequently Asked Questions

What is the difference between Chonluten and Bronchogen?
Both are Khavinson peptide bioregulators targeting respiratory tissue, but with different sequences: Chonluten is Thr-Glu-Asp-Gly while Bronchogen is Ala-Glu-Asp-Leu. They may target different gene regulatory elements within lung tissue. Chonluten is reported to focus on epithelial function while Bronchogen is proposed to target bronchial smooth muscle and mucosal immunity. Both are preclinical research compounds with limited clinical data.

References

  1. 1
    Effect of respiratory peptide bioregulators on lung tissue gene expression(2008)
  2. 2
    Peptide bioregulation of respiratory function in aging(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19